Fly News Breaks for January 15, 2020
Jan 15, 2020 | 07:35 EDT
Raymond James analyst Aaron Kessler downgraded Cardlytics to Market Perform from Outperform without a price target. The analyst cites valuation for the downgrade, saying he thinks the risk reward has become less favorable at current levels and that shares are pricing in a lot of the long-term potential at current levels. Kessler tells investors that while he thinks Cardlytics can reach these long-term numbers, he feels this is largely priced in at the current share price. While downgrading his rating, Kessler says he maintains a positive fundamental view on shares.
News For CDLX From the Last 2 Days
Apr 15, 2021 | 06:45 EDT
Wells Fargo analyst Timothy Willi upgraded Cardlytics to Overweight from Equal Weight with a $150 price target. Willi believes the recent underperformance has created a favorable entry point for shares, and sees several fundamental catalysts over the near to medium term, the analyst tells investors in a research note. The analyst views the risk/reward as favorable at current levels and the liquidity position as stable.